CTLA4 and cancer: For cancer, checkpoint blockade antibodies nivolumab, pembrolizumab (anti-PD1), and ipilimumab (anti-CTLA-4) have achieved unprecedented clinical responses and sparked a revolution in cancer treatment1,2,3,4,5; over 55 antibodies in the United States/European Union have been approved for cancer treatment alone.6